IRLAB-A.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$101M	+79.8%	$-2.57	$-2.57–$-2.57	—	1
2027	$143M	+41.5%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IRLAB-A.STIRLAB Therapeutics AB (publ)	$1.83	-2.45%	$268M	—
ACTI.STActive Biotech AB	$4.00	-0.50%	$106M	—
ALZ.STAlzinova AB (publ)	$0.46	-1.18%	$47M	—
ANNX.STAnnexin Pharmaceuticals AB	$12.70	-0.78%	$91M	—
BIOWKS.STBio-Works Technologies AB (publ)	$3.21	+1.90%	$266M	—
CLS-B.STClinical Laserthermia Systems AB (publ)	$1.89	-0.42%	$60M	—
INIT.STInitiator Pharma A/S	$2.29	-2.55%	$157M	—

Source: Financial Modeling Prep · peers by sector/industry

IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.

www.irlab.se

Employees: 31
IPO / List date: Feb 28, 2017
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds IRLAB-A.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IRLAB-A.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IRLAB-A.ST yet.